openPR Logo
Press release

Nanion Introduces NPC-Certified Cell Lines

11-12-2012 04:40 PM CET | Science & Education

Press release from: Nanion Technologies

Munich, Germany, November 08, 2012; Nanion’s automated patch clamp platforms are known for their high cell compatibility, even for primary cells and stem cells. Nanion now introduces “Nanion Approved Cells”, where commercially available cell lines from several providers have been evaluated and certified based on cell and platform performance. The approved cells can be directly purchased through Nanion, so that Nanion’s customers get a complete package of APC platform and validated assay.
A large number of cell lines from several providers, including Millipore and CreaCell have been validated on Nanion’s three automated patch clamp platforms, the Port-a-Patch, Patchliner, and the SyncroPatch 96. Parameters such as average seal-resistance, access resistance, cell recording longevity, ion channel expression and success rates for completed recordings were investigated and documented in a standardized way. Success rates for completed recordings were typically above 70%. With Nanion Approved Cells, the user can rest assured that the assay will run optimally, with minimal or no assay development required.

Atsushi Ohtsuki, Customer Support Manager, Nanion Technologies, Japan says:
"The Nanion Approved Cells will be much appreciated by Japanese customers, since the optimization work already has been done by Nanion Technologies, which saves time and reduces the risk of an investment. Additionally, it is also a guarantee, that the customers will encounter minimal problems when starting a new assay on Nanion's automated patch clamp platforms."

Dr. Niels Fertig, CEO of Nanion, continues:
"The certification of commercially available cell lines makes it easier for existing and new customers to invest in new cell lines and our platforms without having to worry about lengthy assay development. It is a well-known fact that Nanion's platforms show great compatibility with a broad range of cells and ion channels, which also is confirmed by the long list of Nanion Approved Cells and scientific publications in high impact journals such as Nature or PNAS. Nanion also certifies cell lines on-demand, meaning that if a customer has a particular cell line of interest, we evaluate and document the cell performance on our platforms, free of charge."

About Nanion Approved Cells
Nanion Approved Cells are commercially available cells, certified on Nanion's three automated patch clamp platforms. Cell and platforms performance as well as ion channel current expression is thoroughly investigated and summarized in a data sheet. The approved cells can be directly purchased from Nanion, so that Nanion's customers get a package of APC platform and validated assay. Nanion also does cell line certification on-demand, if the cell line of interest cannot be found in the list of approved cells. The full list of tested cell lines can be found on Nanion's website: http://www.nanion.de/downloads/npc-certified-cells.html

About Nanion Technologies:
Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and globally established three highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery.
Nanion's instruments use planar patch clamp chips which replace the traditional glass pipette used in the technique of patch clamping. Nanion was nominated in 2007 for Germany's most prestigious innovation award the Deutscher Zukunftspreis (German Future Prize, Federal President's Award for Technology and Innovation).

Nanion Technologies GmbH
Gabrielenstr. 9
80636 München
Germany
www.nanion.de

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nanion Introduces NPC-Certified Cell Lines here

News-ID: 242758 • Views: 2014

More Releases from Nanion Technologies

Nanion Starts Shipping the SyncroPatch 384 Patch Engine - a Revolutionary Instru …
The brand-new SyncroPatch 384 Patch Engine (PE) now released by Nanion Technologies propels ion channel drug discovery to a new level. Designed for seamless integration into process-automated drug screening environments, the Patch Engine is equipped with 384 patch clamp amplifiers and an advanced 384 channel liquid handling robot. The SyncroPatch 384PE is the high quality, automated patch clamp system able to finally thrust gold standard electrophysiology from secondary to primary
Nanion Introduces New Product Family: CardioExcyte 96 for Cardiac Toxicity Profi …
Munich, Germany, September 12, 2013; The CardioExcyte 96 is a high resolution device recording contractility in intact cardiomyocyte networks utilizing non-invasive impedance measurements. The system allows cost-efficient, early compound safety profiling using stem cell-derived cardiomyocytes, freshly dissociated cardiomyocytes or beating 3D-cell clusters. Cardiac safety assessment is a vital part of drug development since late withdrawals of compound candidates, due to heart liability issues such as ventricular arrhythmia, are very
Nanion Acquires the SURFE2R Technology for Transporter Protein Analysis
Nanion acquires the well-established SURFE2R technology, allowing state-of-the-art measurements of transporter protein activity and function. The SURFE2R technology is an excellent enhancement to Nanion’s existing products which until now covered ion channels and nanopores. Nanion Technologies is one of the leading providers of high quality automated patch clamp systems. Nanion’s efficient and versatile products drastically improve the data output in patch clamp-based ion channel screening, safety testing and scientific research. Since
Nanion Introduces the Orbit 16 – a Pioneering Device for Parallel Lipid Bilaye …
Munich, Germany, February 23, 2012; Today, Nanion announces the introduction of a completely new product line for efficient analysis of bilayer-reconstituted ion channels and nanopores. The first of these, the Orbit 16, allows for automated formation of, and recordings from 16 bilayers in parallel, combining efficient data generation and ultra-high data quality. The Orbit 16 takes the pain out of bilayer recordings and facilitates efficient data generation through 16

All 5 Releases


More Releases for Cell

Single Cell Analysis Market
Single Cell Analysis Market Size Worth $ 4,752.19 Million By 2026 | CAGR: 18.4% The global Single Cell Analysis market size is expected to reach USD 4,752.19 million by 2026 according to a new study by WhipSmart MI Research. The report “Single Cell Analysis Market By Product (Consumables and Instruments), Cell Type (Human, Microbial and Animal), Technique (Flow Cytometers, Next-Generation Sequencing, Polymerase Chain Reaction, Microscopy, Mass Spectrometry and Other Techniques), Application
Fuel Cell Vehicle Market
The report aims to provide an overview of the global Fuel Cell Vehicle Market with detailed market segmentation by technology, vehicle type, and geography. The global fuel cell vehicle market is expected to witness high growth during the forecast period. The fuel cell vehicle market report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market. Get Sample Copy of
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports. This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions. This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer. Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u Top Key Players: - Becton, Dickinson and Company Biospherix EMD Millipore Eppendorf AG Merck KGaA Sartorius AG VWR International Cell culture is a rapidly emerging
Cell Therapy Market Cell Therapy Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Cell Therapy Necessity for Cell Therapy Treatment 2.1 Emergence of Stem Cell Research 2.2 Benefits of Using the Stem Cell for Research and Treatment Application of Stem Cells in Cell Therapy 3.1 Stem Cells Ability to Differentiate 3.1.1 Totipotent Stem Cells 3.1.2 Pluripotent Stem Cells 3.1.3 Multipotent
Cell Science 2017
It takes us immense pleasure to announce the conference that “Annual Congress on Cell Science, Stem Cell Research & Regenerative Medicine” which is going to be held during November 29-30, 2017 at Atlanta, USA. Cell Science 2017 conference will focus on the latest and exciting innovations in all areas of Cell Biologists and Stem Cell Researchers which offer a unique opportunity for investigators across the globe to meet, network, and perceive